New York City, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Saliva-Based Test Powered by Co-Diagnostics (NASDAQ:CODX) a Game Changer Maxim reiterate Buy with a price target of $30 Earlier this week, ...
The saliva-based CRL Rapid Response Test is focused on getting businesses and schools back to work. Clinical Reference Laboratories CEO Robert Thompson joins Jill Malandrino on Nasdaq #TradeTalks to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback